HRP20100366T1 - Antagonisti receptora progesterona - Google Patents

Antagonisti receptora progesterona Download PDF

Info

Publication number
HRP20100366T1
HRP20100366T1 HR20100366T HRP20100366T HRP20100366T1 HR P20100366 T1 HRP20100366 T1 HR P20100366T1 HR 20100366 T HR20100366 T HR 20100366T HR P20100366 T HRP20100366 T HR P20100366T HR P20100366 T1 HRP20100366 T1 HR P20100366T1
Authority
HR
Croatia
Prior art keywords
pentafluoro
phenyl
dien
hydroxy
pregna
Prior art date
Application number
HR20100366T
Other languages
English (en)
Croatian (hr)
Inventor
Fuhrmann Ulrike
Schmidt Anja
Cleve Arwed
Petrov Orlin
Garke Gunnar
Pruehs Stefan
Brudny-Kloeppel Margarete
Rottmann Antje
Hasselmann Rainer
Schultze-Mosgau Marcus
Moeller Carsten
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of HRP20100366T1 publication Critical patent/HRP20100366T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20100366T 2006-11-15 2007-11-14 Antagonisti receptora progesterona HRP20100366T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten
PCT/EP2007/009997 WO2008058767A1 (en) 2006-11-15 2007-11-14 Progesterone receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20100366T1 true HRP20100366T1 (hr) 2010-07-31

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100366T HRP20100366T1 (hr) 2006-11-15 2007-11-14 Antagonisti receptora progesterona

Country Status (40)

Country Link
US (1) US8053426B2 (cg-RX-API-DMAC10.html)
EP (1) EP2081951B1 (cg-RX-API-DMAC10.html)
JP (1) JP5260537B2 (cg-RX-API-DMAC10.html)
KR (1) KR101494914B1 (cg-RX-API-DMAC10.html)
CN (1) CN101541823B (cg-RX-API-DMAC10.html)
AR (1) AR063813A1 (cg-RX-API-DMAC10.html)
AT (1) ATE465169T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007321848B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718409A2 (cg-RX-API-DMAC10.html)
CA (1) CA2669767C (cg-RX-API-DMAC10.html)
CL (1) CL2007003266A1 (cg-RX-API-DMAC10.html)
CO (1) CO6180443A2 (cg-RX-API-DMAC10.html)
CY (1) CY1110671T1 (cg-RX-API-DMAC10.html)
DE (2) DE102006054535A1 (cg-RX-API-DMAC10.html)
DK (1) DK2081951T3 (cg-RX-API-DMAC10.html)
EA (1) EA017038B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099337A (cg-RX-API-DMAC10.html)
ES (1) ES2343915T3 (cg-RX-API-DMAC10.html)
GT (1) GT200900128A (cg-RX-API-DMAC10.html)
HN (1) HN2009000997A (cg-RX-API-DMAC10.html)
HR (1) HRP20100366T1 (cg-RX-API-DMAC10.html)
IL (1) IL198650A (cg-RX-API-DMAC10.html)
JO (1) JO2672B1 (cg-RX-API-DMAC10.html)
MA (1) MA30990B1 (cg-RX-API-DMAC10.html)
MX (1) MX2009005212A (cg-RX-API-DMAC10.html)
NO (1) NO20092284L (cg-RX-API-DMAC10.html)
NZ (1) NZ576927A (cg-RX-API-DMAC10.html)
PA (1) PA8755801A1 (cg-RX-API-DMAC10.html)
PE (1) PE20081409A1 (cg-RX-API-DMAC10.html)
PL (1) PL2081951T3 (cg-RX-API-DMAC10.html)
PT (1) PT2081951E (cg-RX-API-DMAC10.html)
RS (1) RS51369B (cg-RX-API-DMAC10.html)
SI (1) SI2081951T1 (cg-RX-API-DMAC10.html)
SV (1) SV2009003260A (cg-RX-API-DMAC10.html)
TN (1) TN2009000185A1 (cg-RX-API-DMAC10.html)
TW (1) TW200831109A (cg-RX-API-DMAC10.html)
UA (1) UA98312C2 (cg-RX-API-DMAC10.html)
UY (1) UY30718A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008058767A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200904150B (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
HK1255104A1 (zh) 2015-12-15 2019-08-02 Context Biopharma Inc. 无定形的奥那司酮组合物及其制备方法
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
US20170266204A1 (en) * 2016-03-21 2017-09-21 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
WO1996015794A1 (en) 1994-11-22 1996-05-30 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
IL154974A0 (en) * 2000-10-18 2003-10-31 Schering Ag Inhibition of the growth factor dependency of tumor cells
US20020143000A1 (en) 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE50301507D1 (de) 2002-05-03 2005-12-01 Schering Ag 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
IL198650A0 (en) 2010-02-17
ATE465169T1 (de) 2010-05-15
DE602007006040D1 (de) 2010-06-02
IL198650A (en) 2012-05-31
AU2007321848A1 (en) 2008-05-22
AR063813A1 (es) 2009-02-18
BRPI0718409A2 (pt) 2013-12-17
NZ576927A (en) 2012-01-12
PL2081951T3 (pl) 2010-09-30
GT200900128A (es) 2012-02-01
US8053426B2 (en) 2011-11-08
EA017038B1 (ru) 2012-09-28
CA2669767C (en) 2014-04-01
AU2007321848B2 (en) 2013-09-19
EP2081951B1 (en) 2010-04-21
EA200900635A1 (ru) 2009-12-30
KR101494914B1 (ko) 2015-02-23
JP5260537B2 (ja) 2013-08-14
US20080200440A1 (en) 2008-08-21
ES2343915T3 (es) 2010-08-12
NO20092284L (no) 2009-08-13
CN101541823B (zh) 2012-10-03
CN101541823A (zh) 2009-09-23
DE102006054535A1 (de) 2008-05-21
UA98312C2 (en) 2012-05-10
RS51369B (sr) 2011-02-28
SI2081951T1 (sl) 2010-08-31
HN2009000997A (es) 2011-10-19
KR20090079995A (ko) 2009-07-22
TN2009000185A1 (en) 2010-10-18
MX2009005212A (es) 2009-05-27
ECSP099337A (es) 2009-06-30
PE20081409A1 (es) 2008-12-05
TW200831109A (en) 2008-08-01
PT2081951E (pt) 2010-07-01
MA30990B1 (fr) 2009-12-01
CL2007003266A1 (es) 2008-07-04
HK1136302A1 (en) 2010-06-25
CO6180443A2 (es) 2010-07-19
EP2081951A1 (en) 2009-07-29
SV2009003260A (es) 2009-12-14
UY30718A1 (es) 2008-07-03
JO2672B1 (en) 2012-06-17
DK2081951T3 (da) 2010-08-09
WO2008058767A1 (en) 2008-05-22
CY1110671T1 (el) 2015-06-10
PA8755801A1 (es) 2009-08-26
CA2669767A1 (en) 2008-05-22
ZA200904150B (en) 2010-11-24
JP2010509386A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
JP2010509386A5 (cg-RX-API-DMAC10.html)
ES2671516T3 (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
RU2007101304A (ru) Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение
US20110028564A1 (en) Compositions and methods for treatment of filovirus-mediated diseases
KR101494914B1 (ko) 프로게스테론 수용체 길항제
JP2018530549A5 (cg-RX-API-DMAC10.html)
CA3214530A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
RU2007111711A (ru) Производные трициклического лактама в качестве ингибиторов 11-бэта-гидроксистероидной дегидрогеназы
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
HRP20211124T1 (hr) TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI
JP2020534355A5 (cg-RX-API-DMAC10.html)
JP2005531488A5 (cg-RX-API-DMAC10.html)
EP2725902A2 (en) Anti-viral combination therapy
RU2009107537A (ru) Новые стероидные соединения, обладающие повышенной растворимостью в воде и устойчивостью к метаболизму, и способы их приготовления
CA2611474C (en) Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
HK1223355A1 (zh) 作为ep4配体的苯并咪唑衍生物
CN105873917A (zh) 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
RU2311408C2 (ru) Производные аминотетралина в качестве антагонистов мускаринового рецептора
JP2005504776A5 (cg-RX-API-DMAC10.html)
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
EA200501739A1 (ru) Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний
JP2016065023A (ja) 複素環化合物
JP2008516959A5 (cg-RX-API-DMAC10.html)